Oxford, UK, 3 April 2014 – Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has announced that it will be giving two poster presentations at the AACR Annual Meeting in San Diego, 5-9th April 2014.
Stephen Shuttleworth, Karus’s CSO, will present two posters describing the company’s pre-clinical cancer programmes. The first poster will describe the design and development of a novel series of HDAC6-selective inhibitors, whilst the other will outline Karus’s approach to the development of orally-active, dual-selective PI3K-p110β/δ inhibitors.
The presentations will take place from 1pm to 5pm on 6th April, in the ‘Late-Breaking Research: Cancer Chemistry’ stream, Hall A-E, Poster Section 40.
For more information on Karus’s presentations or for media enquiries, please contact firstname.lastname@example.org.